Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Aug 30–Sep 6, 2026)

· 2 min read

Here’s what’s on the biotech calendar for August 30–September 6: 0 FDA decision dates, 15 trial catalysts, and 0 earnings reports from tracked companies.

🧪 Trial Catalysts & Milestones

  • OSTX — 2026-08-30: LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis
  • OSTX — 2026-08-31: Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemi
  • OSTX — 2026-08-31: Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radia
  • APGE — 2026-09-01: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of
  • SSL — 2026-09-01: Promoting Mental Health Among At-risk Adolescents in Malaysia
  • OSTX — 2026-09-01: Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surger
  • OSTX — 2026-09-01: Comparison of the Effect of Gonadotropin and Clomiphene Citrate Treatment on Sperm Paramet
  • ORIC — 2026-09-01: Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alterat
  • ARVN — 2026-09-01: TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other
  • BHVN — 2026-09-01: Taldefgrobep Alfa in Adults With Overweight and Obesity
  • BHVN — 2026-09-01: Study of BHV-1300 in Graves’ Disease
  • GILD — 2026-09-01: Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis
  • OSTX — 2026-09-01: STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer
  • OSTX — 2026-09-01: Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer A
  • ARV — 2026-09-01: Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surger

📡 Run-up Radar Highlights

Stocks entering the pre-catalyst window with the strongest setups (full radar is a Premium feature):

  • NUVL — NDA in 19 days, score 61/100
  • CYTK — Phase 2 — Recruiting in 2 days, score 59/100
  • SNDX — Phase 2 — Active Trial in 2 days, score 50/100

📈 Last Week’s Biggest Gainers

  • ANF +35.67% (volume 13.9x average)
  • OKTA +28.63% (volume 4.5x average)
  • CRWD +20.50% (volume 2.2x average)
  • ESTC +19.31% (volume 4.9x average)
  • BHVN +17.87% (volume 5.5x average)

Track your tickers on the BioRadar dashboard →

This digest is for informational purposes only and is not investment advice. Always do your own research.

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.